N/A N=440 Family Activation and Communication About Errors and Safety (FACES)
Family Reported Errors and Adverse Events
Primary: Family Safety Reporting Rates — 61; 60 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=135 ADYNOVATE Drug Use-Results Survey
Hemophilia A
Primary: Number of Participants Who Discontinued the Use of Study Drug — 10; 5 Participants
N/A N=46 Measuring and Improving the Safety of Test Result Follow-Up
Lung Cancer · Breast Cancer · Colon Cancer
Primary: Trigger Outcome — 67.0; 65.9; 78.6; 78.1 percentage of abnormal tests w/ followup
N/A N=7,740 Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
Early Phase 1 N=162 Pediatric Reporting of Adult-Onset Genomic Results
Hereditary Breast and Ovarian Cancer Syndrome · Lynch Syndrome · Familial Hypercholesterolemia
Primary: The Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale — 10.32; 8.26; 8.96 units on scale
N/A N=89 (MIST1)-Part 1: Assessment & Feasibility of Post-Symptoms Evaluation
Patient Safety · Manipulation, Spinal
Primary: Number of Patient Encounters That Report a New or Worsening Symptom — 8 Participants
N/A N=314 BeneFIX Drug Use Results Survey [All-Case Surveillance]
Hemophilia B
Primary: Number of Bleeding Episodes (Annual Bleeding Event Rate) During Periodic Replacement Therapy — 2.00 Bleeding events/year
N/A N=101 Study Evaluating Pharmacovigilance Of Refacto AF
Hemophilia A
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 15; 59; 2; 7 participants
N/A N=136 Parent-Reported Symptom Assessments in Children Taking Multiple Medications
Neurologic Disorder · Chronic Disease · Pediatric Disorder
Primary: Global Symptom Score — 12.1 score on a scale
N/A N=6,478 Bringing I-PASS to the Bedside: A Communication Bundle to Improve Patient Safety and Experience
Communication
Primary: Rate of Medical Errors — 41.2; 35.8; 20.0; 22.0 Medical errors per 1000 patient-days
N/A N=16 Family-Authored ICU Diaries to Reduce Fear in Patients Experiencing a Cardiac Arrest (FAID Fear)
Cardiac Arrest · Post Traumatic Stress Syndrome
Primary: Proportion of Eligible Family Members of Cardiac Arrest (CA) Patients Who Agree/Consent to Participate in the Pilot Study — 16; 4; 5 Participants
N/A N=135 Absorb GT1 Japan PMS
Ischemic Heart Disease · Angina Pectoris · Coronary Artery Disease
Primary: Number of Participants With Acute Scaffold Thrombosis (ST) — 0; 0; 0 participants
N/A N=113 Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Treatment-Related Adverse Events of Etanercept — 22 participants
N/A N=7,645 Surveillance for Adverse Events Following Influenza Immunization
Influenza · Vaccines Adverse Reaction
Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation — 153 participants
N/A N=1,197 Electronic Patient Reporting of Symptoms During Cancer Treatment
Metastatic Cancer
Primary: Overall Survival — 42.0; 43.5 percentage of participants
N/A N=156 Eliminating Risk of Preventable Adverse Drug Events at the Hospital-community Interface of Care
Adverse Drug Events
Primary: Health Services Utilization 3 Months Following Hospital Discharge — 3.33; 3.40 Health Services Utilizations — p=.87
N/A N=203 Educational Intervention in Pharmacovigilance for Hospital Health Professionals
Adverse Drug Reaction
Primary: Absolute Number of ADE Reporting (Change Behavior of Health Professionals) — 215; 3 absolute number of adverse drug events
N/A N=87 ReActiv8 Post Market Surveillance Registry
Chronic Low Back Pain
Primary: Low Back Pain - Numeric Pain Rating (NRS) Scale — 4.5; 4.3; 3.8; 3.4 units on a scale
N/A N=6,075 Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care
Colorectal Cancer · Breast Cancer · Coronary Heart Disease
Primary: Number of Subjects Who Discussed Disease Risk With Primary Care Provider — 905; 841 Participants
N/A N=19 The Adverse Drug Reaction (ADRe) Profile for Polypharmacy
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
N/A N=66 Mobile Application to Enhance Medication Management
Medication Adherence · Mobile Application
Primary: Usability of the SAM App — 1.14; 1.32; 1.35; 1.81 score on a scale
N/A N=601 Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)
Essential Hypertension
Primary: Number of Participants Experiencing AEs or ADRs — 184; 59 Participants
N/A N=78 SAFER: A Brief Intervention Involving Family Members in Suicide Safety Planning
Suicide
Primary: Veteran Suicidal Ideation — 1.50; 3.50; 1.00; 3.38 units on a scale — p=.03
N/A N=163 Impacts of Clinician-Mediated Report-Back
Health Knowledge, Attitudes, Practice
Primary: Knowledge Before and After Report-back Intervention. — 0.06; 0.02 Scores on a scale
N/A N=150 Risk Identification of the GlucoTab System in Routine Use
Diabetes Mellitus
Primary: Efficacy: Blood Glucose During Hospital Stay, an Expected Average of 1 Week — 159 mg/dl
N/A N=360 Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima
Acute Pain · Dysmenorrhea
Primary: Percentage of Patients With an Incidence of Adverse Event (AE) Associated to Potential Liver Damage During the Clinical Evaluation of Patients — 0.0 Percentage of Patients
N/A N=23,939 Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in England
Influenza, Human
Primary: Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group — 0.00; 0.00; 0.00; 10.10 Percentage of…
N/A N=451 Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants
N/A N=39 Minimizing Harm From ADEs by Improving Nurse-Physician Communication
Interdisciplinary Communication · Management, Medication Therapy
Primary: Incident Rate for Communication Events — 47.6; 34.74; 34.07 mean events per observation — p=0.01
N/A N=19,334 Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines
Influenza, Human
Primary: Number of Subjects Reporting European Medical Agency (EMA) Defined Adverse Events of Interest (AEIs) (Any) & Onset Dates of AEIs Using a Card Based-adverse Drug Reaction…